SCHEDULE 13G/A: BlackRock, Inc. Discloses 2.0% Stake in FibroBiologics, Inc.
Beneficial Ownership Disclosure
BlackRock, Inc. filed an Amendment No. 2 to Schedule 13G, reporting a 2.0% beneficial ownership stake in FibroBiologics, Inc. as of June 30, 2025.
Summary
- BlackRock, Inc. filed an Amendment No. 2 to Schedule 13G regarding its beneficial ownership of Common Stock in FibroBiologics, Inc.
- As of June 30, 2025, BlackRock, Inc. beneficially owns an aggregate of 750,898 shares of FibroBiologics, Inc. Common Stock.
- This ownership represents 2.0% of the total outstanding class of securities.
- BlackRock, Inc. holds sole voting power over 748,464 shares and sole dispositive power over 750,898 shares.
- No shared voting or dispositive power is reported by BlackRock, Inc.
- The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
- Relevant BlackRock subsidiaries identified include BlackRock Advisors, LLC, BlackRock Fund Advisors, BlackRock Institutional Trust Company, National Association, and BlackRock Investment Management, LLC.
Sentiment
Score: 5
Explanation: Neutral. This is a routine regulatory filing disclosing an institutional ownership stake. It does not contain positive or negative news about the issuer's operations or financial performance, nor does it indicate a significant change in BlackRock's investment thesis beyond a standard update.
Future Outlook
NA
Industry Context
This filing is a routine regulatory disclosure by a major institutional asset manager, BlackRock, Inc., detailing its passive investment stake in a publicly traded company. Such disclosures are standard practice in the financial industry to ensure transparency of significant ownership positions.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Power of Attorney Update | BlackRock, Inc. issued a new Power of Attorney, effective January 21, 2025, revoking the prior one dated April 30, 2023. This new power grants specific individuals (Eric Andruczyk, Richard Cundiff, R. Andrew Dickson, III, Spencer Fleming, Laura Hildner, David Maryles, Christopher Meade, Charles Park, James Raby, Daniel Riemer, David Rothenberg, and Brenda Schulz) the authority to execute and file documents related to ownership or control-person reporting requirements on behalf of BlackRock and its subsidiaries. | 2025-01-21 | Streamlines and formalizes the process for BlackRock's regulatory ownership disclosures, ensuring compliance with reporting requirements. |
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional investor's stake in FibroBiologics, Inc., confirming BlackRock's continued passive investment.
Key Dates
| Date | Description |
|---|---|
| 2023-04-30 | Previous Power of Attorney revoked by the new Power of Attorney. |
| 2025-01-21 | Effective date of the new Power of Attorney for BlackRock, Inc. |
| 2025-06-30 | Date of event which required the filing of this statement (reporting period end date). |
| 2025-07-17 | Signature date of the Schedule 13G Amendment No. 2 filing. |
Keywords
BlackRock, FibroBiologics, SEC filing, Schedule 13G, beneficial ownership, institutional investor, equity stake, common stock
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.